In FY2025, revenue reached 499.7 billion yen (up 14.0% YoY), operating income was 166.7 billion yen (up 6.5% YoY), and net income attributable to owners of the parent was 205.2 billion yen (up 20.4% YoY), marking record highs.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4507-20260512-03.pdf","jir_short_summary":"In FY2025, revenue reached 499.7 billion yen (up 14.0% YoY), operating income was 166.7 billion yen (up 6.5% YoY), and net income attributable to owners of the parent was 205.2 billion yen (up 20.4% YoY), marking record highs.","jir_summary":"### FY2025 Financial Highlights\nIn FY2025, revenue was 499.7 billion yen (up 14.0% YoY), operating income was 166.7 billion yen (up 6.5% YoY), pre-tax profit was 238.9 billion yen (up 19.0% YoY), and net income attributable to owners of the parent was 205.2 billion yen (up 20.4% YoY), all reaching record highs. EBITDA was 187.7 billion yen (up 4.7% YoY). The main factors contributing to the increase in revenue include higher royalty income, increased exports and overseas subsidiaries of domestic pharmaceuticals, and sales expansion of Torii Pharmaceuticals.\n\n### FY2026 Earnings Forecast\nIn FY2026, revenue is projected to be 700.0 billion yen (up 40.1% YoY), operating income 220.0 billion yen (up 32.0% YoY), pre-tax profit 220.0 billion yen (down 7.9% YoY), and net income attributable to owners of the parent 210.0 billion yen (up 2.4% YoY). Revenue and operating income are expected to reach record highs for five consecutive years. The exchange rates are based on USD 1 = 153.0 yen, GBP 1 = 205.0 yen, and EUR 1 = 184.0 yen.","jir_financial_highlights":"Revenue: 499.7 billion yen (up 14.0% YoY)\nOperating Income: 166.7 billion yen (up 6.5% YoY)\nPre-tax Profit: 238.9 billion yen (up 19.0% YoY)\nNet Income Attributable to Owners of the Parent: 205.2 billion yen (up 20.4% YoY)\nEBITDA: 187.7 billion yen (up 4.7% YoY)","jir_category":"","jir_hashtags":"#ShionogiPharmaceutical, #FinancialResultsExplanationMaterials, #JapaneseStocks","jir_key_figures":"Revenue: 499.7 billion yen (up 14.0% YoY)\nOperating Income: 166.7 billion yen (up 6.5% YoY)\nNet Income Attributable to Owners of the Parent: 205.2 billion yen (up 20.4% YoY)","jir_meta_title":"\u3010Shionogi & Co., Ltd.\u3011FY2025 Financial Results\uff5cSales of 499.7 billion yen (+14.0% YoY)","jir_meta_description":"Shionogi & Co., Ltd. achieved record-high FY2025 financial results with sales of 499.7 billion yen, operating income of 166.7 billion yen, and net income attributable to owners of the parent of 205.2 billion yen. Continued growth is expected in FY2026 with sales of 700.0 billion yen.","jir_og_title":"\u3010Shionogi & Co., Ltd.\u3011FY2025 Financial Results\uff5cSales of 499.7 billion yen (+14.0%)","jir_og_description":"Records broken for both sales and profit in FY2025. Growth is expected to accelerate with increased revenue and profit in FY2026.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[4383,4997],\\\"backgroundColor\\\":\\\"#d32f2f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[1566,1667],\\\"backgroundColor\\\":\\\"#1976d2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of the Parent Trend (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024\\\",\\\"FY2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[1704,2052],\\\"backgroundColor\\\":\\\"#388e3c\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"FY2025 Segment Revenue Breakdown (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Medical Pharmaceuticals\\\",\\\"Overseas Subsidiaries\/Exports\\\",\\\"Manufacturing Contracts\\\",\\\"General Pharmaceuticals\\\",\\\"Royalty Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1235,650,151,150,2786],\\\"backgroundColor\\\":[\\\"#f44336\\\",\\\"#2196f3\\\",\\\"#ff9800\\\",\\\"#9c27b0\\\",\\\"#4caf50\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"FY2026 Earnings Forecast vs. FY2025 Actuals (Billion Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating Income\\\",\\\"Pre-tax Profit\\\",\\\"Net Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2025 Actuals\\\",\\\"data\\\":[4997,1667,2389,2052],\\\"backgroundColor\\\":\\\"#90caf9\\\"},{\\\"label\\\":\\\"FY2026 Forecast\\\",\\\"data\\\":[7000,2200,2200,2100],\\\"backgroundColor\\\":\\\"#1976d2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48154","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n